Back to search
FDAFDA · Food and drugs·Recall number Z-1301-2018

Binding Site Optilite Beta-2-Microglobulin Urine Kit, Ref LK043.L.OPT.A, IVD. The firm name on the label is The Binding Site Group Ltd., Birmingham, U.K. The Optilite Beta-2-Microglobulin (¿2M) Urine kit is intended for the quantitative in-vitro measurement of beta-2-microglobulin in urine using the Binding Site Optilite analyser to aid in the diagnosis of active rheumatoid arthritis and kidney disease. This test should be used in conjunction with other laboratory and clinical findings.

Published April 11, 2018 · Recall initiated: March 9, 2018

Summary

FDA records medical device Class II recall Z-1301-2018, published April 11, 2018 and initiated March 9, 2018. Recalling firm: The Binding Site Group, Ltd.; Status: Terminated; Reported quantity: 20 kits distributed to the U.S.; Lot: Lot 407460, UDI 05051700017688. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
The Binding Site Group, Ltd.
Distributor
US Distribution was made to CA. There was no foreign/military/government distribution.
Lot
Lot 407460, UDI 05051700017688
Risk classification
Class II
Area (FDA)
device
Country
United Kingdom

Related recalls

Questions about this recall

Was Binding Site Optilite Beta-2-Microglobulin Urine Kit, Ref LK043.L.OPT.A, IVD. The firm name on the label is The Binding Site Group Ltd., Birmingham, U.K. The Optilite Beta-2-Microglobulin (¿2M) Urine kit is intended for the quantitative in-vitro measurement of beta-2-microglobulin in urine using the Binding Site Optilite analyser to aid in the diagnosis of active rheumatoid arthritis and kidney disease. This test should be used in conjunction with other laboratory and clinical findings. recalled?

Yes. FDA published recall Z-1301-2018 on April 11, 2018. Reported hazard: The product is not meeting the antigen excess protection claim of up to 760mg/L, as stated in the Instructions for Use.

What should I do if I have this product?

Voluntary: Firm initiated · Letter